Switching antifibrotics in patients with idiopathic pulmonary fibrosis: a multi-center retrospective cohort study

Abstract Background Currently, there are two antifibrotics used to treat idiopathic pulmonary fibrosis (IPF): pirfenidone and nintedanib. Antifibrotics slow disease progression by reducing the annual decline of forced vital capacity (FVC), which possibly improves outcomes in IPF patients. During tre...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Yuzo Suzuki, Kazutaka Mori, Yuya Aono, Masato Kono, Hirotsugu Hasegawa, Koshi Yokomura, Hyogo Naoi, Hironao Hozumi, Masato Karayama, Kazuki Furuhashi, Noriyuki Enomoto, Tomoyuki Fujisawa, Yutaro Nakamura, Naoki Inui, Hidenori Nakamura, Takafumi Suda
Formato:	Artigo
Idioma:	Inglês
Publicado em:	BMC 2021-07-01
Colecção:	BMC Pulmonary Medicine
Assuntos:	Antifibrotic therapy Idiopathic pulmonary fibrosis Switch of antifibrotics
Acesso em linha:	https://doi.org/10.1186/s12890-021-01587-3
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!